Umuthi omusha we-Zantrene Cancer uvikela inhliziyo ekufeni

• Umuthi we-Race Oncology i-Zantrene ukhonjiswe ukuvikela amaseli emisipha yenhliziyo yomuntu ekufeni kwe-chemotherapy okubangelwa i-anthracycline. I-Anthracyclines yimithi elwa nomdlavuza esetshenziswa kakhulu futhi esebenza ngempumelelo, nokho ingadala ukulimala okukhulu kwenhliziyo. 
• Ucwaningo lwangaphambi komtholampilo luphinde lwabonisa ikhono le-Zantrene lokusebenzisana nama-anthracycline akhona ukuze abulale kangcono amaseli omdlavuza webele. 
• Ngenxa yokubaluleka kokutholakala, i-Zantrene izobe iphuthunyiswa emtholampilo ngokuhlolwa kweSigaba 2b okuhlelelwe u-2022 ezigulini ezinomdlavuza webele ezisengozini enkulu yokulimala kwenhliziyo okubangelwa i-anthracycline. 
• Inikeza amandla ezimbuyiselo zomtholampilo nezohwebo ezivela ekwenziweni nezinhlanganisela ezintsha ze-Zantrene/anthracycline.

Kungokokuqala ukuthi umuthi ukhombise amandla okukhomba kokubili umdlavuza futhi uvikele inhliziyo emonakalweni we-anthracycline. Lokhu kutholakala kunikeza ithemba elisha ezigidini zeziguli ezinomdlavuza emhlabeni wonke ezilashwa ngamakhemikhali ngama-anthracycline futhi zisengcupheni yokulimala okukhulu nokuhlala unomphela ezinhliziyweni zazo. 

Ama-anthracyclines aziwa kabanzi njengemithi elwa nomdlavuza ephumelela kunazo zonke ezake zenziwa futhi asetshenziswa ezinhlotsheni eziningi zomdlavuza kunanoma isiphi esinye isigaba se-ejenti elwa nomdlavuza.^[1], okuhlanganisa i-leukemia, i-lymphomas, i-neuroblastoma, izinso, isibindi, isisu, isibeletho, i-thyroid, i-ovarian, i-sarcomas, isinye, umdlavuza wamaphaphu nowebele. Kodwa-ke, ukwesaba ngenxa yemiphumela emibi elimazayo ye-anthracyclines enhliziyweni kuye kwaholela kodokotela abaningi be-oncologist ukuba balinganisele ukusebenzisa kwabo le mithi ephumelela kakhulu. Ukutholwa kukaRace kunamandla okuguqula ukusetshenziswa kwe-anthracyclines ngokuvumela izazi ze-oncology ukuthi zisebenzise le mithi enamandla ukuze zikwazi ukulwa nomdlavuza ngaphandle kokwesaba ukulimala okungapheli kwenhliziyo.

I-Zantrene^® Uhlelo lokucwaninga ngezokuphepha kwenhliziyo luholwa abacwaningi abaqavile be-cardiotoxicity, oSolwazi Ababambisene no-Aaron Sverdlov kanye no-Doan Ngo, ngokubambisana nososayensi ohlanganisa umdlavuza uSolwazi Nikki Verrills, eNyuvesi yaseNewcastle.

UProfesa Aaron Sverdlov uthe: “Kuze kube manje, umqondo wezokwelapha ezingase zibe khona zomdlavuza okungezona nje kuphela okungezona eze-cardiotoxic kodwa, empeleni, i-cardio-protective ayikahlolwa noma ijatshuliswe, ikakhulukazi ngenxa 'yezindlela eziqondene nezifo ekunakekelweni kwezempilo. Imiphumela yethu iphakamisa ukuthi i-Zantrene, umuthi osebenza ngempumelelo wokulwa nomdlavuza, inganikeza ngesikhathi esifanayo isivikelo emiphumeleni ewushevu enhliziyweni kusuka kwenye yemithi esetshenziswa kakhulu ngamakhemikhali, i-doxorubicin. Lobu ubufakazi bokuqala bohlobo lwayo ukukhombisa ukuthi kunokwelashwa okuqondiswe kokubili umdlavuza futhi kuvikele inhliziyo! Lokhu kunamandla okwenza ngcono imiphumela yezempilo ezigulini ezinomdlavuza kanye nabasindile abaningi ngokwenza ngcono ukwelashwa kwabo komdlavuza ngenkathi kuvimbela ukukhula kwesifo senhliziyo. ”

Nakuba lokhu kuwukutholwa okusha okujabulisayo, i-Zantrene^® (i-bisantrene dihydrochloride) inomlando omude womtholampilo, owasungulwa ngeminyaka yawo-1970 njengendlela ephephile yenhliziyo esikhundleni se-anthracyclines[2] ngaphambi kokugunyazwa eFrance ngawo-1990s. Ngenkathi ukuphepha kwenhliziyo okuthuthukisiwe kwe-Zantrene kwafakazelwa ezinhlolweni zomtholampilo ezingaphezu kuka-50^[3], , umbuzo wokuthi i-Zantrene ingasiza yini ukuvimbela ukulimala kwenhliziyo okubangelwa i-anthracyclines ayizange ixazululwe.

Ephawula ngemiphumela emisha yocwaningo, oyiChief Scientific Officer kuRace, uDkt Daniel Tillett uthe: “Ukuthola ukuthi i-Zantrene ingavikela inhliziyo ekwelapheni ngamakhemikhali kuyilapho ibulala nomdlavuza kangcono kuwumphumela 'ongcono kunayo yonke yomhlaba' ongavamile. Uma kubhekwa ama-anthracyclines asetshenziswa ezigidini zeziguli ezinomdlavuza minyaka yonke, kunzima ukweqisa amandla omtholampilo nawokuhweba ale mpumelelo!”

iziphetho

• Kule modeli yangaphambi komtholampilo, i-Zantrene ivikela amangqamuzana emisipha yenhliziyo emonakalweni yi-doxorubicin ngenkathi isebenzisana nama-anthracyclines ukubulala kangcono amaseli omdlavuza webele. 
• Umjaho uhambise isicelo selungelo lobunikazi esibhekana nenhlanganisela ye-Zantrene ne-anthracycline ukuze kuvikelwe inhliziyo yeziguli. Le patent (uma inikeziwe) izohlinzeka ngokuvikeleka kwenhlanganisela yomuthi kanye nokusetshenziswa kwawo emtholampilo kuze kube u-2041. 
• Lokhu kutholakala okusha kokuvikela inhliziyo kuzothuthukiswa ngokushesha emtholampilo. Umlando obanzi womtholampilo we-Zantrene uvumela le nhlanganisela ukuthi ithuthuke ngokushesha emtholampilo. 
• Izingxoxo ezithuthukisiwe ziyaqhubeka nodokotela base-Australia ukuze baqhube uhlolo lomtholampilo lweSigaba 2b ezigulini ezinomdlavuza webele ezisengozini enkulu yokulimala kwenhliziyo okubangelwa i-anthracycline. 
• Lokhu okutholakele kuvula amathuba amasha emakethe ye-Zantrene yamandla afanayo omtholampilo nawentengiso ekutholweni kwangaphambilini kokuthi i-Zantrene iyisivimbeli se-FTO esinamandla.

Izinyathelo Okulandelayo

• Izifundo zezilwane zizoqhutshwa ku-Q4 CY2021/ Q1CY2022. 
• Ucwaningo olwengeziwe lwangaphambi komtholampilo ukuze kuphenywe ukuthi i-Zantrene ingayivikela yini inhliziyo emonakalweni ngezinye izidakamizwa ze-chemotherapeutic ezaziwa nangokuthi zidala ukulimala kwenhliziyo. 
• Ucwaningo olwengeziwe lokunquma indlela yamangqamuzana yomsebenzi wokuvikela inhliziyo we-Zantrene. Lokhu kungase kuvumele ukuhlonza imisebenzi eyengeziwe yokuvikela ye-Zantrene. 
• Ukuthuthukiswa kokwakhiwa kwenhlanganisela yezidakamizwa emisha nelungiselelwe ngenani elithuthukisiwe lomtholampilo nelohwebo. 
• Ukuqaliswa kokuhlolwa komtholampilo womdlavuza webele weSigaba 2b ngo-2022.